Search Results - "Clinical lymphoma, myeloma and leukemia"

Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma by Yasuda, Hajime, Tsukune, Yutaka, Watanabe, Naoki, Sugimoto, Kazuya, Uchimura, Ayana, Tateyama, Misa, Miyashita, Yosuke, Ochi, Yusuke, Komatsu, Norio

Get full text

Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment by Okada, Masaya, Imagawa, Jun, Tanaka, Hideo, Nakamae, Hirohisa, Hino, Masayuki, Murai, Kazunori, Ishida, Yoji, Kumagai, Takashi, Sato, Seiichi, Ohashi, Kazuteru, Sakamaki, Hisashi, Wakita, Hisashi, Uoshima, Nobuhiko, Nakagawa, Yasunori, Minami, Yosuke, Ogasawara, Masahiro, Takeoka, Tomoharu, Akasaka, Hiroshi, Utsumi, Takahiko, Uike, Naokuni, Sato, Tsutomu, Ando, Sachiko, Usuki, Kensuke, Mizuta, Syuichi, Hashino, Satoshi, Nomura, Tetsuhiko, Shikami, Masato, Fukutani, Hisashi, Ohe, Yokiko, Kosugi, Hiroshi, Shibayama, Hirohiko, Maeda, Yasuhiro, Fukushima, Toshihiro, Yamazaki, Hirohito, Tsubaki, Kazuo, Kukita, Toshimasa, Adachi, Yoko, Nataduka, Toshiki, Sakoda, Hiroto, Yokoyama, Hisayuki, Okamoto, Takahiro, Shirasugi, Yukari, Onishi, Yasushi, Nohgawa, Masaharu, Yoshihara, Satoshi, Morita, Satoshi, Sakamoto, Junichi, Kimura, Shinya

“…We describe the results of a prospective trial of the discontinuation of second-line dasatinib treatment in chronic myeloid leukemia patients who maintained a…”
Get full text

Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections by Casulo, Carla, Maragulia, Jocelyn, Zelenetz, Andrew D

“…Micro-Abstract Rituximab targets normal B cells and tumor B cells. We used a unique data-mining tool to identify patients with lymphoma who were treated with…”
Get full text

Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma by Gandhi, Ujjawal H., Senapedis, William, Baloglu, Erkan, Unger, Thaddeus J., Chari, Ajai, Vogl, Dan, Cornell, Robert F.

“…Multiple myeloma (MM) is a malignancy of plasma cells that is typically chronic, and relapse is common. Current therapeutic strategies include combination and…”
Get full text

Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis by Avet-Loiseau, Hervé, Ludwig, Heinz, Landgren, Ola, Paiva, Bruno, Morris, Chris, Yang, Hui, Zhou, Kefei, Ro, Sunhee, Mateos, Maria-Victoria

“…Therapeutic advances have greatly extended survival times in patients with multiple myeloma, necessitating increasingly lengthy trials when using survival…”
Get full text

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups by Orlowski, Robert Z., Moreau, Philippe, Niesvizky, Ruben, Ludwig, Heinz, Oriol, Albert, Chng, Wee Joo, Goldschmidt, Hartmut, Yang, Zhao, Kimball, Amy S., Dimopoulos, Meletios

“…The phase III RandomizEd, OpeN Label, Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bortezomib Plus DexamethasOne in Patients With Relapsed Multiple…”
Get full text

Treatment Options for Triple-class Refractory Multiple Myeloma by Mikhael, Joseph

“…The advent of new, more effective, and less toxic therapies has revolutionized the management of multiple myeloma in the past decade. Despite the availability…”
Get full text

Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma by Chari, Ajai, Romanus, Dorothy, Palumbo, Antonio, Blazer, Marlo, Farrelly, Eileen, Raju, Aditya, Huang, Hui, Richardson, Paul

“…Concern has been increasing in oncology regarding randomized clinical trial (RCT) eligibility limiting the generalizability of the findings to real-world…”
Get full text

Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma by Barta, Stefan K., Zain, Jasmine, MacFarlane, Alexander W., Smith, Sonali M., Ruan, Jia, Fung, Henry C., Tan, Carlyn R., Yang, Yibin, Alpaugh, R. Katherine, Dulaimi, Essel, Ross, Eric A., Campbell, Kerry S., Khan, Nadia, Siddharta, Rawat, Fowler, Nathan H., Fisher, Richard I., Oki, Yasuhiro

“…Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are frequently expressed in T-cell lymphomas. This provides a rationale for exploration of…”
Get full text

Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm by Jabbour, Elias, Kantarjian, Hagop, Cortes, Jorge

“…Abstract Although imatinib remains the gold standard for first-line treatment of chronic myeloid leukemia (CML), increasing recognition of imatinib resistance…”
Get full text

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR by Mateos, Maria-Victoria, Sonneveld, Pieter, Hungria, Vania, Nooka, Ajay K., Estell, Jane A., Barreto, Wolney, Corradini, Paolo, Min, Chang-Ki, Medvedova, Eva, Weisel, Katja, Chiu, Christopher, Schecter, Jordan M., Amin, Himal, Qin, Xiang, Ukropec, Jon, Kobos, Rachel, Spencer, Andrew

“…In the phase III CASTOR study in relapsed or refractory multiple myeloma, daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical…”
Get full text

Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update by Battipaglia, Giorgia, Massoud, Radwan, Ahmed, Syed Osman, Legrand, Ollivier, El Cheikh, Jean, Youniss, Riad, Aljurf, Mahmoud, Mohty, Mohamad, Bazarbachi, Ali

“…Patients diagnosed with acute myeloid leukemia (AML) with Fms-like tyrosine kinase 3 (FLT3) mutations have a very poor prognosis, despite use of allogeneic…”
Get full text

Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany by Engelhardt, Monika, Ihorst, Gabriele, Singh, Moushmi, Rieth, Achim, Saba, Grèce, Pellan, Marine, Lebioda, Andrea

“…Real-world health-related quality of life (HRQoL) data in patients with multiple myeloma (MM) are scarce. Here, we report HRQoL by line of therapy in adults…”
Get full text

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma by Ailawadhi, Sikander, Kelly, Kevin R., Vescio, Robert A., Jagannath, Sundar, Wolf, Jeffrey, Gharibo, Mecide, Sher, Taimur, Bojanini, Leyla, Kirby, Maurice, Chanan-Khan, Asher

“…Lorvotuzumab mertansine, a unique antibody–drug conjugate targeting CD56, is frequently expressed on multiple myeloma cells. The present phase I trial of the…”
Get full text

Philadelphia Chromosome–like Acute Lymphoblastic Leukemia by Pui, Ching-Hon, Roberts, Kathryn G., Yang, Jun J., Mullighan, Charles G.

“…Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) is a recently described B-cell precursor ALL with a gene expression profile and a high…”
Get full text

Myeloid Sarcoma: Presentation, Diagnosis and Treatment by Almond, L. Max, Charalampakis, Maria, Dr, Ford, Samuel, Mr, Gourevitch, David, Professor, Desai, Anant, Mr

“…Abstract Myeloid sarcoma is an extramedullary tumour of immature granulytic cells. It is a rare condition, most often associated with acute myeloid leukaemia…”
Get full text

Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients by Al Saleh, Abdullah S., Parmar, Harsh V., Visram, Alissa, Muchtar, Eli, Buadi, Francis K., Go, Ronald S., Dispenzieri, Angela, Kapoor, Prashant, Warsame, Rahma, Lacy, Martha Q., Dingli, David, Leung, Nelson, Gonsalves, Wilson I., Kourelis, Taxiarchis V., Gertz, Morie A., Kyle, Robert A., Rajkumar, S. Vincent, Kumar, Shaji K.

“…Previous reports have suggested that a higher bone marrow plasma-cell percentage (BMPC%) is associated with worse outcomes. However, it is unknown whether…”
Get full text

Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms by Read, Jay A, Koff, Jean L, Nastoupil, Loretta J, Williams, Jessica N, Cohen, Jonathon B, Flowers, Christopher R

“…Micro-Abstract Meta-analyses comparing survival outcomes for diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab and anthracycline-based…”
Get full text

Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia by Richard-Carpentier, Guillaume, Jabbour, Elias, Short, Nicholas J., Rausch, Caitlin R., Savoy, Jonathan M., Bose, Prithviraj, Yilmaz, Musa, Jain, Nitin, Borthakur, Gautam, Ohanian, Maro, Alvarado, Yesid, Rytting, Michael, Kebriaei, Partow, Konopleva, Marina, Kantarjian, Hagop, Ravandi, Farhad

“…Patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) have dismal outcomes. Preclinical studies have suggested that…”
Get full text

A Phase I Study of Midostaurin and Azacitidine in Relapsed and Elderly AML Patients by Cooper, Brenda W, Kindwall-Keller, Tamila L, Craig, Michael D, Creger, Richard J, Hamadani, Mehdi, Tse, William W, Lazarus, Hillard M

“…Micro-Abstract A phase I study of azacitidine 75 mg/m2 intravenously on days 1 to 7 and escalating doses of midostaurin, an oral Fms-like tyrosine kinase 3…”
Get full text